Grand Slam wall may not derail Sun's offer to take Taro private, say analysts
This article was originally published in Scrip
Executive Summary
Grand Slam Asset Management has opposed Sun Pharmaceutical Industries' sweetened offer price for the remaining 34% of Taro Pharmaceutical Industries not held by Sun in Taro, though some analysts say that it is unlikely to completely derail the Indian firm's plans based on Sun's voting might and potential backing of other minority shareholders.